Skip to main content
Retour
LQDA logo

Liquidia Corporation

Qualité des données : 100%
LQDA
NASDAQ Healthcare Biotechnology
35,20 €
▼ 0,30 € (-0,85%)
Cap. Boursière : 3,10B
Fourchette du Jour
34,21 € 36,00 €
Fourchette 52 Semaines
11,26 € 46,67 €
Volume
632 511
Moyenne 50J / 200J
37,72 € / 27,42 €
Clôture Précédente
35,50 €

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Healthcare (627 pairs)

Métrique Action Médiane du Secteur
P/E -45,0 0,3
P/B 69,3 2,9
ROE % -113,0 3,7
Net Margin % -43,5 3,8
Rev Growth 5Y % 87,3 10,0
D/E 4,4 0,2

Objectif de Cours des Analystes

Hold
50,67 € +43.9%
Low: 47,00 € High: 55,00 €
P/E Prévisionnel
14,7
BPA Prévisionnel
2,41 €
Croissance BPA (est.)
+0,0%
CA Est.
590 M

Estimations de Bénéfices

Période BPA Est. CA Est. Analystes
FY2030 6,12 €
3,60 € – 8,34 €
1,4 B 2
FY2029 5,66 €
3,33 € – 7,71 €
1,2 B 4
FY2028 5,09 €
0,44 € – 8,94 €
1,1 B 6

Points Clés

Revenue grew 87,34% annually over 5 years — strong growth
Debt/Equity of 4,42 — high leverage
Negative free cash flow of -40,02M
PEG of 0,83 suggests growth is underpriced
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 943,84%
Capital efficient — spends only 2,74% of revenue on capex

Croissance

Revenue Growth (5Y)
87,34%
Revenue (1Y)1031,18%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
-112,97%
ROIC-15,88%
Net Margin-43,53%
Op. Margin-32,45%

Sécurité

Debt / Equity
4,42
Current Ratio1,40
Interest Coverage-2,13

Valorisation

P/E Ratio
-45,00
P/B Ratio69,31
EV/EBITDAN/A
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 1031,18% Revenue Growth (3Y) 200,88%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 87,34% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 158,32M Net Income (TTM) -68,92M
ROE -112,97% ROA -21,02%
Gross Margin 97,21% Operating Margin -32,45%
Net Margin -43,53% Free Cash Flow (TTM) -40,02M
ROIC -15,88% FCF Growth (3Y) N/A
Safety
Debt / Equity 4,42 Current Ratio 1,40
Interest Coverage -2,13 Dividend Yield 0,00%
Valuation
P/E Ratio -45,00 P/B Ratio 69,31
P/S Ratio 19,59 PEG Ratio 0,83
EV/EBITDA N/A Dividend Yield 0,00%
Market Cap 3,10B Enterprise Value 3,11B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 158,32M 14,00M 17,49M 15,94M 12,85M
Net Income -68,92M -130,39M -78,50M -41,02M -34,58M
EPS (Diluted) -0,80 -1,66 -1,21 -0,67 -0,70
Gross Profit 153,90M 8,12M 14,60M 13,08M 9,83M
Operating Income -51,38M -121,29M -73,38M -38,77M -33,80M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 327,93M 230,31M 118,33M 129,20M 93,73M
Total Liabilities 283,19M 153,04M 71,04M 38,78M 28,46M
Shareholders' Equity 44,75M 77,28M 47,29M 90,42M 65,27M
Total Debt 197,93M 122,39M 49,54M 24,46M 16,08M
Cash & Equivalents 190,68M 176,48M 83,68M 93,28M 57,49M
Current Assets 190,68M 185,11M 89,90M 99,81M 61,28M
Current Liabilities 135,77M 41,78M 18,55M 8,80M 7,33M

Scores de Stratégies

This stock passed the criteria for 1 strategy

Score = fit strength (0–100)
Rank = position among all matches
Custom Full Throttle
#6 of 146
77

Activité Récente

Entré Full Throttle
Mar 24, 2026